

05/08/2009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Atty. Docket No. 06-796)

In the Application of:)
)
 Fanara et al.)
Serial No. 10/599,451) Examiner: Timothy P. Thomas
Filing Date: September 28, 2006) Art Unit: 1614
For: Pharmaceutical Composition of Piperazine) Confirmation No.: 9142
 Derivatives)

RESPONSE TO THE FINAL OFFICE ACTION MAILED FEBRUARY 25, 2009

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Please consider the following amendments and remarks in response to the final Office Action mailed February 25, 2009. No fees are believed to be due, but the Office is nevertheless authorized to charge any fees necessary to maintain the pendency of this application to Deposit Account, No. 13-2490.

Amendments to the claims begin on page 2 of this paper.

Remarks begin on page 5 of this paper.

CERTIFICATE OF TRANSMISSION (37 C.F.R. 1.8)

I hereby certify that this correspondence is being transmitted to the USPTO via the USPTO EFS on April 24, 2009.

Date: April 24, 2009

/Michael S. Greenfield/
Michael S. Greenfield